Apr. 3 at 12:49 AM
$HURA 2025 was a year of execution for TuHURA. We moved forward across multiple programs, with IFx-2.0 advancing in Phase 3, the addition of TBS-2025 expanding our reach into hematologic cancers, and continued progress in our ADC platform.
This progress reflects a deliberate strategy: building beyond a single asset. By investing in R&D and advancing multiple programs in parallel, we are shaping a broader immuno-oncology platform. The
$21.2M raised this year helped us continue moving that vision forward.
At the same time, we strengthened the team behind this effort, with Dr. Craig Tendler stepping into a role aligned with Chief Medical Officer responsibilities. As we look ahead, our focus is on translating this foundation into meaningful clinical milestones, with multiple catalysts expected to drive visibility and accelerate the next phase of growth.
